Loading [MathJax]/jax/output/SVG/jax.js
Research article Topical Sections

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach

  • Received: 05 September 2022 Revised: 26 November 2022 Accepted: 13 December 2022 Published: 16 January 2023
  • Background 

    Drug repurposing is a valuable strategy for rapidly developing drugs for treating COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against SARS-CoV-2 in vitro and in silico.

    Methods 

    The cytotoxicity of lamivudine, emtricitabine, tenofovir, abacavir, efavirenz and raltegravir on Vero E6 was evaluated by MTT assay. The antiviral activity of each of these compounds was evaluated via a pre-post treatment strategy. The reduction in the viral titer was assessed by plaque assay. In addition, the affinities of the antiretroviral interaction with viral targets RdRp (RNA-dependent RNA polymerase), ExoN-NSP10 (exoribonuclease and its cofactor, the non-structural protein 10) complex and 3CLpro (3-chymotrypsin-like cysteine protease) were evaluated by molecular docking.

    Results 

    Lamivudine exhibited antiviral activity against SARS-CoV-2 at 200 µM (58.3%) and 100 µM (66.7%), while emtricitabine showed anti-SARS-CoV-2 activity at 100 µM (59.6%), 50 µM (43.4%) and 25 µM (33.3%). Raltegravir inhibited SARS-CoV-2 at 25, 12.5 and 6.3 µM (43.3%, 39.9% and 38.2%, respectively). The interaction between the antiretrovirals and SARS-CoV-2 RdRp, ExoN-NSP10 and 3CLpro yielded favorable binding energies (from −4.9 kcal/mol to −7.7 kcal/mol) using bioinformatics methods.

    Conclusion 

    Lamivudine, emtricitabine and raltegravir showed in vitro antiviral effects against the D614G strain of SARS-CoV-2. Raltegravir was the compound with the greatest in vitro antiviral potential at low concentrations, and it showed the highest binding affinities with crucial SARS-CoV-2 proteins during the viral replication cycle. However, further studies on the therapeutic utility of raltegravir in patients with COVID-19 are required.

    Citation: Maria I. Zapata-Cardona, Lizdany Florez-Alvarez, Ariadna L. Guerra-Sandoval, Mateo Chvatal-Medina, Carlos M. Guerra-Almonacid, Jaime Hincapie-Garcia, Juan C. Hernandez, Maria T. Rugeles, Wildeman Zapata-Builes. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach[J]. AIMS Microbiology, 2023, 9(1): 20-40. doi: 10.3934/microbiol.2023002

    Related Papers:

    [1] San-Xing Wu, Xin-You Meng . Dynamics of a delayed predator-prey system with fear effect, herd behavior and disease in the susceptible prey. AIMS Mathematics, 2021, 6(4): 3654-3685. doi: 10.3934/math.2021218
    [2] Binfeng Xie, Na Zhang . Influence of fear effect on a Holling type III prey-predator system with the prey refuge. AIMS Mathematics, 2022, 7(2): 1811-1830. doi: 10.3934/math.2022104
    [3] Fatao Wang, Ruizhi Yang, Yining Xie, Jing Zhao . Hopf bifurcation in a delayed reaction diffusion predator-prey model with weak Allee effect on prey and fear effect on predator. AIMS Mathematics, 2023, 8(8): 17719-17743. doi: 10.3934/math.2023905
    [4] Jie Liu, Qinglong Wang, Xuyang Cao, Ting Yu . Bifurcation and optimal harvesting analysis of a discrete-time predator–prey model with fear and prey refuge effects. AIMS Mathematics, 2024, 9(10): 26283-26306. doi: 10.3934/math.20241281
    [5] A. Q. Khan, Ibraheem M. Alsulami . Complicate dynamical analysis of a discrete predator-prey model with a prey refuge. AIMS Mathematics, 2023, 8(7): 15035-15057. doi: 10.3934/math.2023768
    [6] Xiaoming Su, Jiahui Wang, Adiya Bao . Stability analysis and chaos control in a discrete predator-prey system with Allee effect, fear effect, and refuge. AIMS Mathematics, 2024, 9(5): 13462-13491. doi: 10.3934/math.2024656
    [7] Kottakkaran Sooppy Nisar, G Ranjith Kumar, K Ramesh . The study on the complex nature of a predator-prey model with fractional-order derivatives incorporating refuge and nonlinear prey harvesting. AIMS Mathematics, 2024, 9(5): 13492-13507. doi: 10.3934/math.2024657
    [8] Weili Kong, Yuanfu Shao . Bifurcations of a Leslie-Gower predator-prey model with fear, strong Allee effect and hunting cooperation. AIMS Mathematics, 2024, 9(11): 31607-31635. doi: 10.3934/math.20241520
    [9] Yaping Wang, Yuanfu Shao, Chuanfu Chai . Dynamics of a predator-prey model with fear effects and gestation delays. AIMS Mathematics, 2023, 8(3): 7535-7559. doi: 10.3934/math.2023378
    [10] Jing Zhang, Shengmao Fu . Hopf bifurcation and Turing pattern of a diffusive Rosenzweig-MacArthur model with fear factor. AIMS Mathematics, 2024, 9(11): 32514-32551. doi: 10.3934/math.20241558
  • Background 

    Drug repurposing is a valuable strategy for rapidly developing drugs for treating COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against SARS-CoV-2 in vitro and in silico.

    Methods 

    The cytotoxicity of lamivudine, emtricitabine, tenofovir, abacavir, efavirenz and raltegravir on Vero E6 was evaluated by MTT assay. The antiviral activity of each of these compounds was evaluated via a pre-post treatment strategy. The reduction in the viral titer was assessed by plaque assay. In addition, the affinities of the antiretroviral interaction with viral targets RdRp (RNA-dependent RNA polymerase), ExoN-NSP10 (exoribonuclease and its cofactor, the non-structural protein 10) complex and 3CLpro (3-chymotrypsin-like cysteine protease) were evaluated by molecular docking.

    Results 

    Lamivudine exhibited antiviral activity against SARS-CoV-2 at 200 µM (58.3%) and 100 µM (66.7%), while emtricitabine showed anti-SARS-CoV-2 activity at 100 µM (59.6%), 50 µM (43.4%) and 25 µM (33.3%). Raltegravir inhibited SARS-CoV-2 at 25, 12.5 and 6.3 µM (43.3%, 39.9% and 38.2%, respectively). The interaction between the antiretrovirals and SARS-CoV-2 RdRp, ExoN-NSP10 and 3CLpro yielded favorable binding energies (from −4.9 kcal/mol to −7.7 kcal/mol) using bioinformatics methods.

    Conclusion 

    Lamivudine, emtricitabine and raltegravir showed in vitro antiviral effects against the D614G strain of SARS-CoV-2. Raltegravir was the compound with the greatest in vitro antiviral potential at low concentrations, and it showed the highest binding affinities with crucial SARS-CoV-2 proteins during the viral replication cycle. However, further studies on the therapeutic utility of raltegravir in patients with COVID-19 are required.


    Abbreviations

    PDB ID:

    Protein Data Bank identification code; 

    RdRp:

    RNA-dependent RNA polymerase; 

    ExoN-NSP10:

    Exoribonuclease and its cofactor, the non-structural protein 10 complex; 

    3CLpro:

    3-chymotrypsin-like cysteine protease

    In population ecology, understanding how predators and primary producers influence nutrient flow relative to each other is important. Ecosystem interactions and predator-prey relationships are governed by predation and the delivery of resource processes. The identification of ecological factors that can alter or control dynamic behavior requires theoretical and experimental research. One way to study these questions is by means of experimental control, and another useful way is via mathematical modeling as well as computer simulations. Over decades of theoretical ecology and biomathematics development, mathematical modeling has become an indispensable tool for scientists in related fields to study ecosystems. Since Lotka [1] and Volterra [2], as cornerstones of theoretical ecology, published the first study of predator-prey dynamics, any species in nature can be a predator or prey, and due to its prevalence, it has become one of the most popular topics for researchers to study [3,4,5]. Besides, because biological resources are renewable and have the most unique development mechanisms, the over-utilization of biological resources and the destruction of the environment by humans will directly affect the balance of the ecosystem. Maintaining ecological balance and meeting humans material needs have attracted the most attention from researchers focused on the scientific management of renewable resource development [6,7,8].

    Shelter serves as a defense strategy. It refers broadly to a series of behaviors by prey to avoid predators in order to increase their survival rate. The concept of sanctuary was first developed by Maynard-Smith [9] and Gause et al. [10], and its popularity has been very high, garnering widespread attention from many scholars [11,12,13,14,15]. Sih et al.[16] investigated the effects of prey refuge in a three-species model and concluded that the system's stability is strongly related to the refuge. Also, similar findings can be displayed in [17,18,19,20,21,22]. The two modes of refuge analyzed by Gonzalez-Olivares et al. [17] have diverse stability domains in terms of the parameter space. Qi et al.[21] ensure the stability of the system by varying the strength of the refuge.

    Through reviewing a large amount of literature, we begin to consider [23,24] as a basis for the two prey and one predator species that will be modeled in this article. We assume that at a certain time t, the populations of the two prey and one predator are x1(t), x2(t), and y(t), respectively. Based on the above, we construct the following model:

    {dx1dt=r1x1(1x1K1)a1x1x2c1(1m1)x1yq1E1x1,dx2dt=r2x2(1x2K2)a2x1x2c2(1m2)x2yq2E2x2,dydt=e1(1m1)x1y+e2(1m2)x2ydyq3E3y. (1.1)

    The significance of the full parameters is annotated in Table 1.

    Table 1.  Biological meaning of parameters.
    Parameters Biological meaning
    r1,r2 Growth rates of prey x1 and prey x2
    K1,K2 Carrying capacity of prey x1 and prey x2
    a1,a2 Interspecific competition between prey x1 and prey x2
    c1,c2 Predation coefficients for prey x1 and prey x2
    m1,m2 Refuge rates of prey x1 and prey x2
    e1,e2 Conversion factors for prey x1 and prey x2
    q1,q2,q3 Captureability factors for prey x1, prey x2 and predator y
    E1,E2,E3 Harvesting efforts for prey x1, prey x2 and predator y
    d Predator y mortality rate

     | Show Table
    DownLoad: CSV

    Most species in nature, including humans, are influenced by fear. Fear may cause an abnormal state and behavior to arise. As usual, prey have an innate fear of predators. The ecology of fear is related to combining the optimal behavior of prey and predators with their population densities [25,26]. In view of reality, it is a fact that prey fear predators, which is seen as a psychological effect that can have a lasting impact on prey populations. This psychological influence is often easy to overlook, but it is necessary to consider it in the context of practical ecology [27]. Wang et al. [28] first considered the effect of the fear factor on the model and first proposed the fear of prey F(k,y). Afterwards, some researchers have investigated the effects of the fear effect and predator interferences in some three-dimensional systems as well as explored the generation of Hopf bifurcation conditions in the presence of a fear parameter as a bifurcation parameter [29,30,31,32]. Zanette et al. [33] observed that prey will reduce reproducing because of fear of being killed by predators, thus decreasing the risk of being killed after giving birth, which also leads directly to a decline in prey birth rates. According to the above discussion, our paper considers the different fears ki caused by predators for the two prey species.

    In reality, when prey feel the crisis of being hunted, they will reproduce less and increase their survival rate. These conditions about the fear factor F(ki,y) (i=1,2) are listed as follows:

    1) F(0,y)=1: prey production does not decrease when the prey does not fear the predator;

    2) F(ki,0)=1: even though the prey will develop a fear of predators and there will be no predators, prey production will still not decline;

    3) limkiF(ki,y)=0: when the prey's fear of the predator is very high, this will result in the prey production tending to zero;

    4) limyF(ki,y)=0: prey have a fear of predators, and when predator numbers are too large, this can also lead to prey production tending to zero;

    5) F(ki,y)ki<0: the greater the prey's fear of predators, the less productive it will be;

    6) F(ki,y)y<0: predators are inversely proportional to their prey.

    For ease of analysis, we draw on Wang et al. [28] to consider the fear effect:

    F(ki,y)=11+kiy(i=1,2), (1.2)

    obviously, F(ki,y) (i=1,2) in (1.2) satisfies conditions 1)6). Based on the above conditions, this study will consider the effect of fear on system (1.1) to obtain system (1.3).

    {dx1dt=r1x11+k1y(1x1K1)a1x1x2c1(1m1)x1yq1E1x1,dx2dt=r2x21+k2y(1x2K2)a2x1x2c2(1m2)x2yq2E2x2,dydt=e1(1m1)x1y+e2(1m2)x2ydyq3E3y. (1.3)

    Notably, most biological parameters in much of the literature are fixed constants. However, in reality, the survival of species is full of unknowns, and all data are not always constant, which can lead to deviations from the ideal model with fixed parameters. In order to make the model more relevant and the results more accurate, we cannot just consider fixed parameters. Therefore, to make the study more convincing, it is necessary to target imprecise parameters. Professor Zadeh [34], who first proposed the fuzzy set theory, also argued that the application of fuzzy differential equations is a more accurate method for modeling biological dynamics in the absence of accurate data conditions [35]. Moreover, the first introduction of the idea of fuzzy derivatives came from Chang and Zadeh [36]. Further, Kaleva [37] studied the generalized fuzzy derivatives based on Hukuhara differentiability, the Zadeh extension principle, and the strong generalized differentiability concept. Bede et al. [38] employed the notion of strongly generalized differentiability to investigate fuzzy differential equations. Khastan and Nieto [39] solved the margin problem for fuzzy differential equations in their article. Motivated by the method of Pal [13] and Wang [23], we assume that the imprecise parameters ~r1, ~r2, ~a1, ~a2, ~c1, ~c2, ~e1, ~e1 and ˜d represent all triangular fuzzy numbers (the relevant theories of fuzzy sets are detailed in Appendix A), then the system (1.3) can be written as

    {~dx1dt=~r1x11+k1y(1x1K1)~a1x1x2~c1(1m1)x1yq1E1x1,~dx2dt=~r2x21+k2y(1x2K2)~a2x1x2~c2(1m2)x2yq2E2x2,~dydt=~e1(1m1)x1y+~e2(1m2)x2y˜dyq3E3y, (1.4)

    we cut these imprecise parameters ~r1, ~r2, ~a1, ~a2, ~c1, ~c2, ~e1, ~e1, and ˜d by using α-level. System (1.4) can be expressed as follows:

    {(dx1dt)αL=rα1Lx11+k1yrα1R1+k1yx21K1aα1Rx1x2cα1R(1m1)x1yq1E1x1,(dx1dt)αR=rα1Rx11+k1yrα1L1+k1yx21K1aα1Lx1x2cα1L(1m1)x1yq1E1x1,(dx2dt)αL=rα2Lx21+k2yrα2R1+k2yx22K2aα2Rx1x2cα2R(1m2)x2yq2E2x2,(dx2dt)αR=rα2Rx21+k2yrα2L1+k2yx22K2aα2Lx1x2cα2L(1m2)x2yq2E2x2,(dydt)αL=eα1L(1m1)x1y+eα2L(1m2)x2ydαRyq3E3y,(dydt)αR=eα1R(1m1)x1y+eα2R(1m2)x2ydαLyq3E3y. (1.5)

    Introducing weighted sum, we change (1.5) to (1.6)

    {dx1dt=w1(dx1dt)αL+w2(dx1dt)αR,dx2dt=w1(dx2dt)αL+w2(dx2dt)αR,dydt=w1(dydt)αL+w2(dydt)αR, (1.6)

    where w1 and w2 are satisfied with w1+w2=1, and w1,w20. Simplifying the system (1.6), we obtain

    {dx1dt=A11+k1yx1A21+k1yx21K1A3x1x2A4(1m1)x1yq1E1x1,dx2dt=B11+k2yx2B21+k2yx22K2B3x1x2B4(1m2)x2yq2E2x2,dydt=C1(1m1)x1y+C2(1m2)x2yC3yq3E3y, (1.7)

    where

    A1=w1rα1L+w2rα1R,  A2=w1rα1R+w2rα1L,  A3=w1aα1R+w2aα1L,A4=w1cα1R+w2cα1L,  B1=w1rα2L+w2rα2R,  B2=w1rα2R+w2rα2L,B3=w1aα2R+w2aα2L,  B4=w1cα2R+w2cα2L,  C1=w1eα1L+w2eα1R,C2=w1eα2L+w2eα2R,  C3=w1dαR+w2dαL.

    The rest of the paper is shown below: In Section 2, we first prove the nonnegativity and boundedness of the system (1.7). Sections 3 and 4 discuss all possible equilibria and give conditions for the local asymptotic stability and global asymptotic stability of the equilibria. Immediately after that, in Section 5, we analyze the Hopf bifurcation by using the normal form theory. In Section 6, we numerically simulate the theoretical results of Sections 4 and 5. Finally, the article ends with detailed conclusions.

    In this section, we give the following theorem to ensure the boundedness and nonnegativity of the solutions of the system (1.7).

    Theorem 2.1. Provided that the initial values x1(0)>0, x2(0)>0, and y(0)>0, all solutions of system (1.7) are nonnegative.

    Proof. It is not difficult to find that the right half of the system (1.7) fulfills the local Lipschitzian condition. Integrating both sides of the system (1.7) at the same time yields

    x1(t)=x1(0)[expt0(A11+k1yA21+k1yx1K1A3x2A4(1m1)yq1E1)ds]>0,x2(t)=x2(0)[expt0(B11+k2yB21+k2yx2K2B3x1B4(1m2)yq2E2)ds]>0,y(t)=y(0)[expt0(C1(1m1)x1C2(1m2)x2C3q3E3)ds]>0. (2.1)

    If the solution curve starts at any internal point of R3+={(x1(t),x2(t),y(t))R3:x1(t)0, x2(t)0, y(t)0}, then x1(t), x2(t), and y(t) will always be nonnegative.

    Theorem 2.2. Assume that the initial values x1(0), x2(0), and y(0) are all greater than zero. The feasible region Ω is a positive invariant set of the system (1.7) defined by

    Ω={(x1(t),x2(t),y(t))R3+:C1A4x1(t)+C2B4x2(t)+y(t)ϕμ},
    (i.e  Ω={(x1(t),x2(t),y(t))R3+:w1eα1L+w2eα1Rw1cα1R+w2cα1Lx1(t)+w1eα2L+w2eα2Rw1cα2R+w2cα2Lx2(t)+y(t)ϕμ}),

    where μ=min{q1E1,q2E2,C3+q3E3}.

    Proof. Define a function

    W(t)=C1A4x1(t)+C2B4x2(t)+y(t). (2.2)

    After taking the derivative on both sides of (2.2), we obtain

    dWdt=C1A4dx1dt+C2B4dx2dt+dydt. (2.3)

    Furthermore, we can obtain

    dWdt+μW=C1A4(1+k1y)(A1x1A2x21K1)C1A3A4x1x2C1(1m1)x1ydWdt+μW=+C2B4(1+k2y)(B1x2B2x22K2)C2B3B4x1x2C2(1m2)x2ydWdt+μW=+C1(1m1)x1y+C2(1m2)x2yC3yq3E3y+C1μA4x1dWdt+μW=C1A4q1E1x1C2B4q2E2x2+C2μB4x2+μy,dWdt+μW=C1A4(1+k1y)(A1x1A2x21K1)+C2B4(1+k2y)(B1x2B2x22K2)dWdt+μW=+C1A4x1(μq1E1)+C2B4x2(μq2E2)+y(μC3q3E3)dWdt+μW=(C1A3A4+C2B3B4)x1x2, (2.4)

    where μ=min{q1E1,q2E2,C3+q3E3}. Let ϕ1=A21K14A2,ϕ2=B21K24B2, ϕC1A4ϕ1+C2B4ϕ2, we have

    dWdt+μWC1A4ϕ1+C2B4ϕ2=ϕ. (2.5)

    Therefore, it can be deduced that

    Wϕμ+Neμt, (2.6)

    where N is a positive constant. Then we can further obtain

    lim suptWϕμ, (2.7)

    which indicates that the feasible domain Ω is a positive invariant set.

    In this section, we discuss the existence of all equilibria in the system (1.7). All equilibria for system (1.7) are provided by

    (1) Trivial equilibrium P1=(0,0,0).

    (2) Axial equilibrium P2=(xς1,0,0) exists if A1>q1E1, where xς1=K1(A1q1E1)A2.

    (3) Axial equilibrium P3=(0,xΥ2,0) exists if B1>q2E2, where xΥ2=K2(B1q2E2)B2.

    (4) Axial equilibrium P4=(xΨ1,0,yΨ) exists if A1A2xΨ1K1+q1E1 and Δ1>A4(1m1)+k1q1E1, where

    xΨ1=C3+q3E3C1(1m1),yΨ=Δ1(A4(1m1)+k1q1E1)2k1A4(1m1),Δ1=4(k1A4(1m1))(A1A2xΨ1K1q1E1)+(A4m1A4k1q1E1)2. (3.1)

    (5) Axial equilibrium P5=(0,xν2,yν) exists if B1B2xν2K2+q2E2 and Δ2>B4(1m2)+k2q2E2, where

    xν2=C3+q3E3C2(1m2),yν=Δ2(B4(1m2)+k2q2E2)2k2B4(1m2),Δ2=4(k2B4(1m2))(B1B2xν2K2q2E2)+(B4m2B4k2q2E2)2. (3.2)

    (6) Axial equilibrium P6=(xι1,xι2,0) exists if B1>B3xι1+q2E2, K1K2A3B3>A2B2 and A3B1K2+B2q1E1>A3K2q2E2+A1B2, where

    xι1=A3K1K2(B1q2E2)+K1B2(q1E1A1)K1K2A3B3A2B2,xι2=K2(B1B3xι1q2E2)B2. (3.3)

    (7) Internal equilibrium P7=(x1,x2,y) exists, and its value will be given in the proof of Theorem 3.1.

    Theorem 3.1. When g3>0 and g4g5<0 are met, there is an internal equilibrium P7.

    Proof. We derive that from the second equation of the system (1.7)

    g1y2+g2y+g3=0, (3.4)

    where

    g1=k2B4(1m2),  g2=k2B3x1B4(1m2)q2E2k2,  g3=(B1x2K2B2B3x1q2E2).

    It follows from the Descartes law of signs that Eq (3.4) has one and only one solution y greater than zero if and only if g3>0, i.e., B1>x2K2B2+B3x1+q2E2. Substituting y into the algebra expression on the right side of the first equation of the system (1.7) equals zero; furthermore, we obtain

    x2=A1A3+A3k1yA2x1K1A3+K1A3k1yA4(1m1)yA3q1E1A3. (3.5)

    Introduce (3.5) into the right side of the third equation of the system (1.7), which meets zero, it simplifies to obtain

    g4x1g5=0, (3.6)

    where

    g4=[C1(1m1)A2C2(1m2)K1A3+K1A3k1y],g5=[A1C2(1m2)A3+A3k1yA4C2(1m1)(1m2)yA3C2q3E3(1m2)A3C3q3E3].

    Reusing the Descartes law of signs, we can assert that there exists at least one positive solution x1 of Eq (3.6) if and only if g4g5<0. And then we can deduce that

    x2=A1A3+A3k1yA2x1K1A3+K1A3k1yA4(1m1)yA3q1E1A3.

    then the interior equilibrium P7(x1,x2,y) exists.

    In this section, the Jocabian matrix will be used to prove the local stability of all equilibria. Moreover, we prove the global stability of the internal equilibrium P7 by constructing a Lyapunov function.

    The Jocabian matrix for system (1.7) is given below:

    M=(M11M12M13M21M22M23M31M32M33), (4.1)

    where

    M11=A11+k1y2A21+k1yx1K1A3x2A4(1m1)yq1E1,M12=A3x1,M13=k1A1x1(1+k1y)2+k1A2(1+k1y)2x21K1A4(1m1)x1,M21=B3x2,M22=B11+k2y2B21+k2yx2K2B3x1B4(1m2)yq2E2,M23=k2B1x2(1+k2y)2+k2B2(1+k2y)2x22K2B4(1m2)x2,M31=C1(1m1)y,M32=C2(1m2)y,  M33=C1(1m1)x1+C2(1m2)x2C3q3E3. (4.2)

    Through simple calculation, we directly draw the conclusion that trivial and axial equilibria are locally asymptotically stable:

    (1) P1(0,0,0) is locally asymptotically stable if

    A1q1E1<0andB1q2E2<0. (4.3)

    (2) P2(xς1,0,0) is locally asymptotically stable if

    B1q2E2<B3xς1q2<B3(C3+q3E3)C1(1m1)q2. (4.4)

    (3) P3(0,xΥ2,0) is locally asymptotically stable if

    A1q1E1<A3xΥ2q1<A3(C3+q3E3)C2(1m2)q1. (4.5)

    (4) P4(xΨ1,0,yΨ) is locally asymptotically stable if

    B1q2(1+k2yΨ)E2<B3xΨ1+B4(1m2)yΨq2. (4.6)

    (5) P5(0,xν2,yν) is locally asymptotically stable if

    A1q1(1+k1yν)E1<A3xν2+A4(1m1)yνq1. (4.7)

    (6) P6(xι1,xι2,0) is locally asymptotically stable if

    C1(1m1)xι1+C2(1m2)xι2<C3+q3E3. (4.8)

    We draw the conclusion that the internal equilibrium P7(x1,x2,y) is locally asymptotically stable from the proof of Theorem 4.1.

    Theorem 4.1. The internal equilibrium P7 is locally asymptotically stable if it exists and the following conditions are fulfilled:

    ψ1>0,ψ1ψ2>0,ψ3>0. (4.9)

    Proof. The Jocabian matrix of system (1.7) at (x1,x2,y) is

    (L1L2L3L4L5L6L7L8L9), (4.10)

    where

    L1=A2(1+k1y)x1K1<0,L2=A3x1<0,L3=k1A1x1(1+k1y)2A4(1m1)x1+k1A2(1+k1y)2(x1)2K1,L4=B3x2<0,L5=B2(1+k2y)x2K2<0,L6=k2B1x2(1+k2y)2B4(1m2)x2+k2B2(1+k2y)2(x2)2K2,L7=C1(1m1)y>0,L8=C2(1m2)y>0,L9=0. (4.11)

    Therefore, the characteristic equation at P7 can be expressed as

    η3+ψ1η2+ψ2η+ψ3=0, (4.12)

    where

    ψ1=L1L5,ψ2=L1L5L6L8L3L7L2L4,ψ3=L8(L1L6L3L4)+L7(L3L5+L2L6). (4.13)

    The Routh-Hurwitz criterion shows that the internal equilibrium P7 is locally asymptotically stable; the following conditions need to be met: ψ1>0, ψ1ψ2>0, and ψ3>0.

    This subsection studies the global asymptotic stability of interior equilibrium P7.

    Theorem 4.2. If condition 4Γ1Γ2l1l2A2B2(1+k1y)(1+k2y) > (l1A3+l2B3)2 (i.e. 4Γ1Γ2l1l2(w1rα1R+w2rα1L)(w1rα2R+w2rα2L)(1+k1y)(1+k2y) > (l1(w1aα1R+w2aα1L)+l2(w1aα2R+w2aα2L))2) holds, then P7 is globally asymptotically stable.

    Proof. We construct a Lyapunov function:

    V(x1,x2,y)=l1[x1x1x1ln(x1x1)]+l2[x2x2x2ln(x2x2)]  +yyyln(yy). (4.14)

    Obviously, xixixiln(xixi)0 (i=1,2) and yyyln(yy)0, thus V0. Taking the derivative of V(x1,x2,y) over t, one has

    dVdt=l1(x1x1x1)dx1dt+l2(x2x2x2)dx2dt+yyydydt, (4.15)

    where

    x1x1x1dx1dt=k1A1(1+k1y)(1+k1y)(x1x1)(yy)A2(x1x1)2K1(1+k1y)(1+k1y)x1x1x1dx1dt=A2k1(x1yx1y)K1(1+k1y)(1+k1y)(x1x1)A3(x1x1)(x2x2)x1x1x1dx1dt=A4(1m1)(x1x1)(yy),x2x2x2dx2dt=k2B1(1+k2y)(1+k2y)(x2x2)(yy)B2(x2x2)2K2(1+k2y)(1+k2y)x2x2x2dx2dt=B2k2(x2yx2y)K2(1+k2y)(1+k2y)(x2x2)B3(x1x1)(x2x2)x2x2x2dx2dt=B4(1m2)(x2x2)(yy),yyydydt=C1(1m1)(x1x1)(yy)+C2(1m2)(x2x2)(yy). (4.16)

    To simplify the calculation, let

    x1yx1y=y(x1x1)x1(yy),  x2yx2y=y(x2x2)x2(yy),Γ1=1K1(1+k1y)(1+k1y),  Γ2=1K2(1+k2y)(1+k2y),l1=C1(1m1)Γ1k1(K1A1+A2x1)+A4(1m1),  l2=C2(1m2)Γ2k2(K2B1+B2x2)+A4(1m1). (4.17)

    We obtain

    dVdt={Γ1l1A2(1+k1y)(x1x1)2+(l1A3+l2B3)(x1x1)(x2x2)+Γ2l2B2(1+k2y)(x2x2)2}dVdt  =YGY, (4.18)

    where

    Y=[(x1x1),(x2x2)],  G=(Γ1l1A2(1+k1y)l1A3+l2B32l1A3+l2B32Γ2l2B2(1+k2y)).

    Therefore, dVdt<0 if and only if 4Γ1Γ2l1l2A2B2(1+k1y)(1+k2y)>(l1A3+l2B3)2.

    In this section, we will use the normal form theory introduced by Hassard et al.[40] and the central manifold theory [41] to study the Hopf bifurcation of the system (1.7). When the system (1.7) undergoes Hopf bifurcation, the corresponding characteristic equation must have a pair of conjugate pure imaginary roots, that is,

    η1,2=±iω,i=1. (5.1)

    Consider the parameter k1 as a bifurcation parameter. When the value of parameter k1 changes near the critical point kΞ1 of Hopf bifurcation, the pure imaginary roots ±iω will become a complex eigenvalue η=ρ+i˜ω. Substituting η=ρ+i˜ω into Eq (4.12), we need to separate the imaginary and real parts to get

    ρ3+ψ3+ρψ2+ρ2ψ13ρ˜ω2ψ1˜ω2=0, (5.2)
    3ρ2˜ω+ψ2˜ω+2ρψ1˜ω˜ω3=0. (5.3)

    By simplifying Eqs (5.2) and (5.3), we obtain

    ψ38ρ32ρψ28ρ2ψ1ψ1ψ22ρψ21=0, (5.4)

    at k1=kΞ1, taking the derivative of Eq (5.4) over k1 yields

    dρdk1|k1=kΞ1=12(dψ3dk1ψ1dψ2dk1ψ2dψ1dk1)/(ψ2+ψ21). (5.5)

    If it satisfies dρdk1|k1=kΞ10, the system (1.7) will generate Hopf bifurcation, which indicates that when parameter k1 crosses the bifurcation critical point kΞ1, the population state evolves from stable equilibrium to periodic oscillation over time.

    When the system (1.7) undergoes Hopf bifurcation at k1=kΞ1, the final decision condition is also met. Considering that the characteristic roots of Eq (4.12) are η1,2=±iω and η3=ψ1, in order to obtain this condition, we introduce

    z1=x1x1,z2=x2x2,z3=yy. (5.6)

    Substituting (5.6) into the system (1.7) and separating the linear and nonlinear parts, it can be obtained that

    (˙z1˙z2˙z3)=J(P7)(z1z2z3)+(F1(z1,z2,z3)F2(z1,z2,z3)F3(z1,z2,z3)), (5.7)

    where

    F1(z1,z2,z3)=2j1+j2+j33tj1j2j3zj11zj22zj33+O((|z1|+|z2|+|z3|)4),F2(z1,z2,z3)=2j1+j2+j33nj1j2j3zj11zj22zj33+O((|z1|+|z2|+|z3|)4),F3(z1,z2,z3)=2j1+j2+j33lj1j2j3zj11zj22zj33+O((|z1|+|z2|+|z3|)4), (5.8)

    where O((|z1|+|z2|+|z3|)4) is a fourth-order polynomial function about variables (|z1|,|z2|,|z3|), while tj1j2j3, nj1j2j3, and lj1j2j3 can be obtained through calculation:

    t101=A1k12(1+k1y)2+A2k1(1+k1y)2x1K1A4(1m1)2,  t002=A1x1k21(1+k1y)3A2k21(1+k1y)3(x1)2K1,t102=A1k213(1+k1y)3A2k213(1+k1y)32x1K1,  t003=A1x1k31(1+k1y)4+A2k31(1+k1y)4(x1)2K1,t110=A32,  t200=A21+k1y1K1,  t201=A2k13(1+k1y)21K1,t011=t020=t030=t012=t021=t111=t120=t210=t300=0,n011=B1k22(1+k2y)2+B2k2(1+k2y)2x2K2B4(1m2)2,  n002=B1x2k22(1+k2y)3B2k22(1+k2y)3(x2)2K2,n012=B1k223(1+k2y)3B2k223(1+k2y)32x2K2,  n003=B1x2k32(1+k2y)4+B2k32(1+k2y)4(x2)2K2,n110=B32,  n020=B21+k2y1K2,  n021=B2k23(1+k2y)21K2,n101=n200=n030=n111=n120=n102=n210=n201=n300=0,l101=C1(1m1)2,  l011=C2(1m2)2,l110=l200=l020=l002=l030=l003=l012=l021=l111=l120=l102=l210=l201=l300=0. (5.9)

    By introducing a reversible transformation

    (z1z2z3)=(101q21q22q23q31q32q33)(y1y2y3), (5.10)

    which q21q32q22q31+q22q33q23q320, the expression for the coefficient qij(i=2,3;j=1,2,3) is

    q21=L2L3L4L6+L1L3L5L6L1L2L26+L3L6ω2L23L4L5L23L252L2L3L5L6+L22L26+L23ω2,q22=(L23L4L1L3L6+L3L5L6L2L6)ωL23L252L2L3L5L6+L22L26+L23ω2,q23=L1L6L6η3L3L4L3L5L2L6L3η3,q31=L2L3L4L5L1L3L25L22L4L6+L1L2L5L6L1L3ω2L2L6ω2L23L252L2L3L5L6+L22L26+L23ω2,q32=ω(L1L2L6+L2L5L6L2L3L4L3L25L3ω2)L23L252L2L3L5L6+L22L26+L23ω2,q33=L2L4L1L5+L1η3+L5η3η23L3L5L2L6L3η3, (5.11)

    Li(i=1,2,,9) is defined in (4.11). So the standard type of system (5.7) can be written as

    (˙y1˙y2˙y3)=(0ω0ω0000η3)(y1y2y3)+(~F1(y1,y2,y3)~F2(y1,y2,y3)~F3(y1,y2,y3)), (5.12)

    where

    (~F1(y1,y2,y3)~F2(y1,y2,y3)~F3(y1,y2,y3))=(101q21q22q23q31q32q33)1(F1(z1,z2,z3)F2(z1,z2,z3)F3(z1,z2,z3)). (5.13)

    In Eq (5.13), the coefficients of polynomial ˜F(y1,y2,y3) are ˜tj1j2j3, ˜nj1j2j3 and ˜lj1j2j3.

    Based on the central manifold theory, use the center manifold Wc(0,0,0) existing at the origin to reduce the dimension of the system (5.12), that is

    Wc(0,0,0)={(y1,y2,y3)R3|y3=h(y1,y2),h(0,0)=0,Dh(0,0)=0}, (5.14)

    where

    h(y1,y2)=1v1+v23hv1v2y1y2+O((|y1|+|y2|)4). (5.15)

    Through calculation, we can obtain

    h10=h01=h11=0,h20=˜l200+˜l020ω2η3(1+ω4),h02=˜l020˜l200ω21+ω4,h30=1(1+ω4)(η23+ω6)(˜l200˜n101˜l300η32˜l020˜n200η3ω+˜l020˜n101ω2+˜l011˜l020ω3h30=˜l030ω3+2˜l200˜n200η3ω3˜l300η3ω4˜l011˜l200ω5˜l030ω7),h21=(˜l200+˜l020ω2)(˜l011η3+2˜t200η3ω+˜n110η23ω32˜t110ω4+˜n101η3ω52˜n020η3ω6)η3(1+ω4)(η23+ω6)h21=˜l020(2˜n110η3ω+˜n101ω32˜n020ω4)η23+ω6,h12=(˜l200+˜l020ω2)(2˜t110η3ω˜n101η23ω2+˜l011ω3+2˜n020η23ω3+2˜t200ω4+2˜n110η3ω6)η3(1+ω4)(η23+ω6)h12=˜l020(2˜n020η3ω+2˜n110ω4˜n101η3)η23+ω6,h03=(˜l200+˜l020ω2)(˜l011η23+ω2+˜n101ω3+2˜n200η3ω6)η3(1+ω4)(η23+ω6)h03=+˜l011˜l020η3˜l030η3+˜l300ω3+2˜l020˜n200ω4η23+ω6. (5.16)

    Correspondingly, the dynamic properties of the system are limited to the central flow Wc(0,0,0), and in conjunction with Eq (5.14), system (5.12) can be simplified as

    (˙y1˙y2)=(U(y1,y2)N(y1,y2)), (5.17)

    where

    U(y1,y2)=ωy2+1y21+2y1y2+3y22+4y31+5y21y2+6y1y22+7y32,N(y1,y2)=ωy1+ȷ1y21+ȷ2y1y2+ȷ3y22+ȷ4y31+ȷ5y21y2+ȷ6y1y22+ȷ7y32, (5.18)

    in the formula, we have

    1=˜t200,2=˜t110,3=˜t020,4=h20˜t101+˜t300,5=˜t210,6=h02˜t101,7=0,ȷ1=˜n200,ȷ2=˜n110,ȷ3=˜n020,ȷ4=˜n300,ȷ5=h20˜n011,ȷ6=0,ȷ7=h02˜n011+˜n030. (5.19)

    We introduce the partial derivative sign

    Uy1(ykΞ1)=Uy1,  3Uy21y2(ykΞ1)=Uy1y1y2,  2Ny22(ykΞ1)=Ny2y2,  , (5.20)

    where subscripts y1 and y2 indicate partial derivatives for the first and second variable, respectively. Based on Eq (5.18), it can be obtained that Uy1=0, Uy20, Ny10, Ny2=0, and Uy2Ny10. In addition, it ensures that the system (5.18) has pure virtual feature roots ±i|Uy2Ny1|. Thus, it can be determined that system (1.7) produces Hopf bifurcation; the direction of the bifurcation is determined by the following equation:

    QkΞ1=116ω(3+5+ȷ5+ȷ7)+116ω(13ȷ2ȷ3ȷ1ȷ2ȷ11). (5.21)

    Theorem 5.1. If dρdk1|k1=kΞ10, then system (1.7) will generate Hopf bifurcation at interior equilibrium P7. In addition, when dρdk1|k1=kΞ1<0, if QkΞ1<0 and 0<k1kΞ11, then system (1.7) will generate supercritical Hopf bifurcation and form a stable periodic orbit, or if QkΞ1>0 and 0<k1kΞ11, then system (1.7) will generate subcritical Hopf bifurcation and form a stable periodic orbit.

    In this section, we first discussed equilibria P1 to P7 of system (1.7) with distinct values of α, w1, and w2. Consider the parameter values as follows: ~r1=(2.8,3,3.2), ~r2=(2.8,3,3.2), ~c1=(0.1,0.2,0.3), ~c2=(0.5,0.6,0.7), ~a1=(0.1,0.2,0.3), ~a2=(0.2,0.3,0.4), ~e1=(0.2,0.3,0.4), ~e2=(0.3,0.4,0.5), and ˜d=(0.1,0.2,0.3). Tables 28 showed that the trivial equilibrium P1 retained constant at (0, 0, 0), the values of prey x1, prey x2, and predator y always maintained at 0; the values of prey x1 in P2 and prey x2 in P3 severally decreased with increasing w1 under the same α; the values of prey x1 and predator y in P4 increased with increasing w1, and for P5 the value of prey x2 and predator y rose with growing w1; the values of prey x1 and x2 in P6 decreased with growing w1; and for the same α, considering interior equilibrium P7, the values of prey x1, prey x2, and predator y decreased with growing w1.

    Table 2.  The trivial equilibrium P1 for k1=0.1, k2=0.7, q1=0.7, q2=0.5, q3=0.7, E1=0.3, E2=0.2, E3=0.2, K1=5, K2=5, m1=0.9, m2=0.3.
    w1 w2 P1 at α=0 P1 at α=0.3 P1 at α=0.6 P1 at α=0.9
    0 1 (0,0,0) (0,0,0) (0,0,0) (0,0,0)
    0.2 0.8 (0,0,0) (0,0,0) (0,0,0) (0,0,0)
    0.4 0.6 (0,0,0) (0,0,0) (0,0,0) (0,0,0)
    0.6 0.4 (0,0,0) (0,0,0) (0,0,0) (0,0,0)
    0.8 0.2 (0,0,0) (0,0,0) (0,0,0) (0,0,0)
    1 0 (0,0,0) (0,0,0) (0,0,0) (0,0,0)

     | Show Table
    DownLoad: CSV
    Table 3.  The axial equilibrium P2 for k1=0.1, k2=0.7, q1=0.7, q2=0.5, q3=0.7, E1=0.3, E2=0.2, E3=0.2, K1=5, K2=5, m1=0.9, m2=0.3.
    w1 w2 P2 at α=0 P2 at α=0.3 P2 at α=0.6 P2 at α=0.9
    0 1 (5.3393,0,0) (5.1224,0,0) (4.9144,0,0) (4.7148,0,0)
    0.2 0.8 (5.0521,0,0) (4.9280,0,0) (4.8069,0,0) (4.6888,0,0)
    0.4 0.6 (4.7804,0,0) (4.7409,0,0) (4.7017,0,0) (4.6629,0,0)
    0.6 0.4 (4.5230,0,0) (4.5608,0,0) (4.5988,0,0) (4.6372,0,0)
    0.8 0.2 (4.2788,0,0) (4.3872,0,0) (4.4980,0,0) (4.6116,0,0)
    1 0 (4.0469,0,0) (4.2197,0,0) (4.3994,0,0) (4.5861,0,0)

     | Show Table
    DownLoad: CSV
    Table 4.  The axial equilibrium P3 for k1=0.7, k2=0.1, q1=0.7, q2=0.5, q3=0.7, E1=0.3, E2=0.2, E3=0.2, K1=5, K2=5, m1=0.3, m2=0.9.
    w1 w2 P3 at α=0 P3 at α=0.3 P3 at α=0.6 P3 at α=0.9
    0 1 (0,5.5357,0) (0,5.3147,0) (0,5.1027,0) (0,4.8993,0)
    0.2 0.8 (0,5.2431,0) (0,5.1166,0) (0,4.9932,0) (0,4.8728,0)
    0.4 0.6 (0,4.9662,0) (0,4.9260,0) (0,4.8861,0) (0,4.8465,0)
    0.6 0.4 (0,4.7039,0) (0,4.7424,0) (0,4.7812,0) (0,4.8202,0)
    0.8 0.2 (0,4.4551,0) (0,4.5655,0) (0,4.6785,0) (0,4.7942,0)
    1 0 (0,4.2187,0) (0,4.3949,0) (0,4.5779,0) (0,4.7682,0)

     | Show Table
    DownLoad: CSV
    Table 5.  The axial equilibrium P4 for k1=0.3, k2=0.7, q1=0.7, q2=0.5, q3=0.7, E1=0.3, E2=0.2, E3=0.2, K1=20, K2=20, m1=0.2, m2=0.6.
    w1 w2 P4 at α=0 P4 at α=0.3 P4 at α=0.6 P4 at α=0.9
    0 1 (0.4800,0,0.1496) (0.5838,0,0.1767) (0.7059,0,0.2040) (0.8516,0,0.2317)
    0.2 0.8 (0.6222,0,0.1858) (0.6971,0,0.2022) (0.7802,0,0.2188) (0.8732,0,0.2354)
    0.4 0.6 (0.8000,0,0.2224) (0.8306,0,0.2280) (0.8623,0,0.2335) (0.8954,0,0.2391)
    0.6 0.4 (1.0286,0,0.2595) (0.9902,0,0.2539) (0.9534,0,0.2484) (0.9181,0,0.2428)
    0.8 0.2 (1.3333,0,0.2969) (1.1845,0,0.2801) (1.0551,0,0.2633) (0.9415,0,0.2465)
    1 0 (1.7600,0,0.3343) (1.4261,0,0.3062) (1.1692,0,0.2782) (0.9655,0,0.2502)

     | Show Table
    DownLoad: CSV
    Table 6.  The axial equilibrium P5 for k1=0.3, k2=0.7, q1=0.7, q2=0.5, q3=0.7, E1=0.3, E2=0.2, E3=0.2, K1=20, K2=20, m1=0.8, m2=0.6.
    w1 w2 P5 at α=0 P5 at α=0.3 P5 at α=0.6 P5 at α=0.9
    0 1 (0,0.1920,0.3638) (0,0.2298,0.3833) (0,0.2727,0.4029) (0,0.3220,0.4226)
    0.2 0.8 (0,0.2435,0.3899) (0,0.2697,0.4016) (0,0.2981,0.4134) (0,0.3291,0.4252)
    0.4 0.6 (0,0.3048,0.4160) (0,0.3150,0.4199) (0,0.3255,0.4239) (0,0.3363,0.4278)
    0.6 0.4 (0,0.3789,0.4422) (0,0.3668,0.4383) (0,0.3551,0.4343) (0,0.3437,0.4304)
    0.8 0.2 (0,0.4706,0.4683) (0,0.4268,0.4566) (0,0.3872,0.4448) (0,0.3513,0.4330)
    1 0 (0,0.5867,0.4942) (0,0.4970,0.4748) (0,0.4222,0.4553) (0,0.3590,0.4357)

     | Show Table
    DownLoad: CSV
    Table 7.  The axial equilibrium P6 for k1=0.3, k2=0.4, q1=0.7, q2=0.5, q3=0.7, E1=0.6, E2=0.1, E3=0.2, K1=5, K2=5, m1=0.9, m2=0.4.
    w1 w2 P6 at α=0 P6 at α=0.3 P6 at α=0.6 P6 at α=0.9
    0 1 (4.9826,3.8455,0) (4.6419,3.5356,0) (4.3385,3.2568,0) (4.0671,3.0043,0)
    0.2 0.8 (4.5369,3.4395,0) (4.3577,3.2745,0) (4.1901,3.1191,0) (4.0331,2.9724,0)
    0.4 0.6 (4.1543,3.0858,0) (4.1016,3.0366,0) (4.0500,2.9883,0) (3.9995,2.9408,0)
    0.6 0.4 (3.8232,2.7740,0) (3.8700,2.8184,0) (3.9177,2.8636,0) (3.9665,2.9097,0)
    0.8 0.2 (3.5351,2.4958,0) (3.6599,2.6172,0) (3.7926,2.7447,0) (3.9338,2.8789,0)
    1 0 (3.2834,2.2448,0) (3.4690,2.4307,0) (3.6742,2.6311,0) (3.9017,2.8485,0)

     | Show Table
    DownLoad: CSV
    Table 8.  The interior equilibrium P7 for k1=0.4, k2=0.5, q1=0.6, q2=0.4, q3=0.2, E1=0.2, E2=0.3, E3=0.2, K1=100, K2=100, m1=0.9, m2=0.3.
    w1 w2 P7 at α=0 P7 at α=0.3
    0 1 (1.7240,3.6276,1.1986) (1.5910,3.4597,1.0271)
    0.2 0.8 (1.6168,3.5123,1.0583) (1.5042,3.3223,0.9139)
    0.4 0.6 (1.5417,3.4296,0.9337) (1.4211,3.1793,0.8023)
    0.6 0.4 (1.4309,3.2886,0.7930) (1.3913,3.1413,0.7269)
    0.8 0.2 (1.4291,3.2451,0.6884) (1.3195,3.0467,0.6350)
    1 0 (1.3764,2.9890,0.5245) (1.2797,2.9766,0.5529)
    w1 w2 P7 at α=0.6 P7 at α=0.9
    0 1 (1.7066,3.7444,1.0113) (1.5325,3.4231,0.7999)
    0.2 0.8 (1.5291,3.4203,0.8678) (1.4899,3.3773,0.7762)
    0.4 0.6 (1.5273,3.4215,0.8306) (1.4789,3.3677,0.7638)
    0.6 0.4 (1.4894,3.3737,0.7779) (1.4685,3.3587,0.7516)
    0.8 0.2 (1.4594,3.3320,0.7279) (1.4590,3.3504,0.7397)
    1 0 (1.4328,3.2552,0.6687) (1.4124,3.2841,0.7105)

     | Show Table
    DownLoad: CSV

    Considering four sets of different initial values, it could be seen from Figure 1 that different orbits eventually converged to the same value, which concluded that the interior equilibrium of the system (1.7) fulfills the character of globally asymptotical stability. Figure 2 plotted the bifurcation graph of system (1.7) with the horizontal coordinates k1, and the Hopf bifurcation of the system occurred with k1 taking values in the range of 0.01k10.7. When 0.01k1<0.384, the system oscillates periodically, while it maintains a stable steady-state when 0.384<k10.7. Therefore, based on Figure 2, it could be concluded that the fear of prey x1 for predator y affected the stability of the system. We further observed that as k1 increased, the prey x1 density continued to decrease while the predator y density kept increasing. Thus, the result also suggested that greater fear of predators had a negative impact on prey populations while having a positive impact on predator populations. Correspondingly, Figures 3 and 4 showed the waveform plots and phase diagram at k1=0.1 and k1=0.7, respectively.

    Figure 1.  Global stability of the internal equilibrium P7 = (5.665, 1.668, 2.047) of system (1.7) is given by the following parameter values: α=1, w1+w2=1, A1=2.0, A2=2.0, B1=2.0, B2=2.0, k1=0.2, k2=0.1, q1=0.4, q2=0.4, q3=0.2, E1=0.2, E2=0.2, E3=0.2, A3=0.1, B3=0.1, A4=0.3, B4=0.6, K1=10, K2=10, m1=0.4, m2=0.4, C1=0.1, C2=0.2, C3=0.5.
    Figure 2.  Hopf bifurcation occurs as a bifurcation parameter k1, and the remaining parameters take the following values: α=1, w1+w2=1, A1=3.0, A2=3.0, B1=3.0, B2=3.0, k2=0.4, q1=0.6, q2=0.4, q3=0.2, E1=0.2, E2=0.2, E3=0.2, A3=0.2, B3=0.1, A4=0.3, B4=0.6, K1=10, K2=70, m1=0.9, m2=0.3, C1=0.1, C2=0.2, C3=0.5.
    Figure 3.  Waveform plots and phase diagram of system (1.7) with k1=0.1, and α=1, w1+w2=1.
    Figure 4.  Waveform plots and phase diagram of system (1.7) with k1=0.7, and α=1, w1+w2=1.

    In addition, Figure 5 also plots the bifurcation graph with changing m1. As can be seen in Figure 5, m1 took values from 0.3 to 1, in which the system also underwent a Hopf bifurcation. When the value m1 ranged from 0.3 to 0.657, the system (1.7) was stable; nevertheless, it would become unstable at 0.657<m11. Correspondingly, Figures 6 and 7 showed the waveform plots and phase diagram at m1=0.6 and m1=0.9, respectively.

    Figure 5.  Hopf bifurcation occurs as a bifurcation parameter of system (1.7) parameter m1, and the remaining parameters take the following values: α=1, w1+w2=1, A1=2.0, A2=2.0, B1=2.0, B2=2.0, k1=0.1, k2=0.4, q1=0.7, q2=0.4, q3=0.2, E1=0.2, E2=0.2, E3=0.3, A3=0.1, B3=0.1, A4=0.3, B4=0.6, K1=10, K2=70, m2=0.4, C1=0.1, C2=0.2, C3=0.5.
    Figure 6.  Waveform plots and phase diagram of system (1.7) with m1=0.6 and α=1, w1+w2=1.
    Figure 7.  Waveform plots and phase diagram of system (1.7) with m1=0.9 and α=1, w1+w2=1.

    Further, we find an interesting dynamic phenomenon through some numerical simulations. System (1.7) appears as a chaotic phenomenon, as shown in Figure 8.

    Figure 8.  Waveform plots and phase diagram of chaotic phenomena with the following parameter values: α=1, w1+w2=1, A1=2.0, A2=2.0, B1=3.0, B2=3.0, k1=0.2, k2=0.5, q1=0.6, q2=0.4, q3=0.2, E1=0.2, E2=0.3, E3=0.2, A3=0.2, B3=0.3, A4=0.3, B4=0.6, K1=10, K2=70, m1=0.9, m2=0.3, C1=0.1, C2=0.2, C3=0.5.

    In this work, we develop a model of one-predator and two-prey interactions in a fuzzy environment, examine the effects of fear and prey refuge on the system, and provide insight into the dynamic complexity. The proofs of the theoretical parts of this paper are based on system (1.7). It has been proven that all equilibria in system (1.7) are locally asymptotically stable, and interior equilibrium P7 is also globally asymptotically stable. We have been further concerned about the appearance and direction of Hopf bifurcation. With the support of theoretical research, our numerical simulations have been able to display a wealth of charts and graphs.

    First of all, different equilibria are displayed from Tables 28 with different α,w1,w2, respectively. Throughout Figure 1, we have verified the global asymptotical stability of interior equilibrium P7, and find that the system is from unstable to stable with the increase of fear k1, which demonstrates that the fear effect may be an important factor influencing the stability of the system (see Figures 24). Furthermore, it has also been observed that an increase in prey refuge m1 leads to oscillatory phenomena (see Figures 57). Finally, through studying the Hopf bifurcation, we have discovered some interesting biological phenomena, namely that system (1.7) appears to be in a chaotic state (see Figure 8).

    Xuyang Cao: Conceptualization, Investigation, Methodology, Validation, Writing-original draft, Formal analysis, Software; Qinglong Wang: Conceptualization, Methodology, Formal analysis, Writing-review and editing, Supervision; Jie Liu: Validation, Visualization, Data curation.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    The authors thank the editor and referees for their careful reading and valuable comments.

    The work is supported by the Natural Science Foundation of Hubei Province (No. 2023AFB1095) and the National Natural Science Foundation of China (No. 12101211) and the Program for Innovative Research Team of the Higher Education Institution of Hubei Province (No. T201812) and the Teaching Research Project of Education Department of Hubei Province (No. 2022367) and the Graduate Education Innovation Project of Hubei Minzu University (Nos. MYK2024071, MYK2023042).

    The authors declare that there are no conflicts of interest regarding the publication of this paper.

    Definition 1. [34] Fuzzy set: A fuzzy set ˜ in a universe of discourse S is denoted by the set of pairs

    ˜={(s,μ˜(s)):sS},

    where the mapping μ˜:S[0,1] is the membership function of the fuzzy set ˜ and μ˜ is the membership value or degree of membership of sS in the fuzzy set ˜.

    Definition 2. [42] α-cut of fuzzy set: For any α(0,1], the α-cut of fuzzy set ˜ defined by α={s:μ˜(s))α} is a crisp set. For α=0 the support of ˜ is defined as 0=Supp(˜)=¯{sR,μ˜(s)>0}.

    Definition 3. [43] Fuzzy number: A fuzzy number satisfying the property S=R is called a convex fuzzy set.

    Definition 4. [44] Triangular fuzzy number: A triangular fuzzy number (TFN) ˜(b1,b2,b3) represent fuzzy set of the real line R satisfying the property that the membership function μ˜:R[0,1] can be espressed by

    μ˜={sb1b2b1  if  b1sb2,b3sb3b2  if  b2sb3,0otherwise.

    Hence, the α-cut of triangular fuzzy number meets boundedness and encapsulation on [L(α),R(α)], in which L(α)=infs:μ˜(s)α=b1+α(b2b1) and R(α)=sup{s:μ˜(s)α}=b3+α(b3b2).

    Lemma 1. [45] In weighted sum method, wj stands for the weight of jth objective. wjgj represent a utility function for jth objective, and the total utility function π is represented by

    π=ljwjgj,j=1,2,,l,

    where wj>0 and ljwj=1 are satisfied.


    Acknowledgments



    We want to thank to Instituto Nacional de Salud, Bogota-Colombia, for donating the Vero E6 cell line.

    Conflicts of interest



    The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study was supported by Universidad de Antioquia (strategy # UdeA responde al COVID-19), CODI (Act 2020–36850) and Universidad Cooperativa de Colombia. BPIN 2020000100131-SGR.

    Author contributions



    Study conception and design: MTR, WZB, CGA, AGS, JHG and JCH. Data collection, analysis and interpretation of results: MZC, LFA and AGS Draft manuscript preparation: MZC, LFA, AGS and MMC. Assistance with interpretation of the results and manuscript writing: MTR, WZB, CGA, JHG and JCH. Guide and review research: MTR and WZB. All authors have contributed to editing this paper; they have approved this final submission.

    [1] W.H.O.WHO Director-General' opening remarks at the media briefing on COVID-19-11 March 2020, 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
    [2] Lopera TJ, Chvatal-Medina M, Florez-Alvarez L, et al. (2022) Humoral response to BNT162b2 vaccine against SARS-CoV-2 variants decays after six months. Front Immunol 13: 879036. https://doi.org/10.3389/fimmu.2022.879036
    [3] Tada T, Zhou H, Dcosta BM, et al. (2021) Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience 24: 103341. https://doi.org/10.1016/j.isci.2021.103341
    [4] Hoffmann M, Kruger N, Schulz S, et al. (2022) The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185: 447-456. https://doi.org/10.1016/j.cell.2021.12.032
    [5] Wang MY, Zhao R, Gao LJ, et al. (2020) SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 10: 587269. https://doi.org/10.3389/fcimb.2020.587269
    [6] Yadav R, Chaudhary JK, Jain N, et al. (2021) Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 10: 821. https://doi.org/10.3390/cells10040821
    [7] Yang H, Rao Z (2021) Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol 19: 685-700. https://doi.org/10.1038/s41579-021-00630-8
    [8] Gao Y, Yan L, Huang Y, et al. (2020) Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368: 779-782. https://doi.org/10.1126/science.abb7498
    [9] Lin S, Chen H, Chen Z, et al. (2021) Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity. Nucleic Acids Res 49: 5382-5392. https://doi.org/10.1093/nar/gkab320
    [10] Baddock H, Brolih S, Yosaatmadja Y, et al. (2022) Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification. Nucleic Acids Res 50: 1484-1500. https://doi.org/10.1093/nar/gkab1303
    [11] V'kovski P, Kratzel A, Steiner S, et al. (2021) Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19: 155-170. https://doi.org/10.1038/s41579-020-00468-6
    [12] Mosquera-Yuqui F, Lopez-Guerra N, Moncayo-Palacio EA (2020) Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations. J Biomol Struct Dyn 40: 2010-2023. https://doi.org/10.1080/07391102.2020.1835716
    [13] Peele KA, Potla Durthi C, Srihansa T, et al. (2020) Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked 19: 100345. https://doi.org/10.1016/j.imu.2020.100345
    [14] Cao B, Wang Y, Wen D, et al. (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382: 1787-1799. https://doi.org/10.1056/NEJMoa2001282
    [15] Arabi YM, Gordon AC, Derde LPG, et al. (2021) Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med 47: 867-886. https://doi.org/10.1007/s00134-021-06448-5
    [16] Beck BR, Shin B, Choi Y, et al. (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J 18: 784-790. https://doi.org/10.1016/j.csbj.2020.03.025
    [17] Jordaan MA, Ebenezer O, Damoyi N, et al. (2020) Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. Heliyon 6: e04642. https://doi.org/10.1016/j.heliyon.2020.e04642
    [18] Indu P, Rameshkumar MR, Arunagirinathan N, et al. (2020) Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J Infect Public Health 13: 1856-1861. https://doi.org/10.1016/j.jiph.2020.10.015
    [19] Jockusch S, Tao C, Li X, et al. (2020) Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase. bioRxiv : 2020. https://doi.org/10.1101/2020.04.03.022939
    [20] Alavian G, Kolahdouzan K, Mortezazadeh M, et al. (2021) Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review. J Clin Pharmacol 61: 581-590. https://doi.org/10.1002/jcph.1788
    [21] Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2: a007161. https://doi.org/10.1101/cshperspect.a007161
    [22] Kumar Y, Singh H, Patel CN (2020) In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health 13: 1210-1223. https://doi.org/10.1016/j.jiph.2020.06.016
    [23] Jo S, Kim S, Yoo J, et al. (2021) A study of 3CLpros as promising targets against SARS-CoV and SARS-CoV-2. Microorganisms 9: 756. https://doi.org/10.3390/microorganisms9040756
    [24] Garcia-Trejo JJ, Ortega R, Zarco-Zavala M (2021) Putative repurposing of lamivudine, a nucleoside/nucleotide analogue and antiretroviral to improve the outcome of cancer and COVID-19 patients. Front Oncol 11: 664794. https://doi.org/10.3389/fonc.2021.664794
    [25] Clososki CG, Soldi RA, Moreira Silva R, et al. (2020) Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc 31: 1552-1556. https://doi.org/10.21577/0103-5053.20200106
    [26] Copertino D, Lima B, Duarte R, et al. (2020) Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. J Biomol Struct Dyn 40: 7367-7380. https://doi.org/10.26434/chemrxiv.12250199
    [27] Chien M, Anderson TK, Jockusch S, et al. (2020) Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res 19: 4690-4697. https://doi.org/10.1021/acs.jproteome.0c00392
    [28] Xie X, Muruato AE, Zhang X, et al. (2020) A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun 11: 5214. https://doi.org/10.1038/s41467-020-19055-7
    [29] Martinec O, Huliciak M, Staud F, et al. (2019) Anti-HIV and anti-Hepatitis C virus drugs inhibit P-Glycoprotein efflux activity in Caco-2 Cells and precision-cut rat and human intestinal slices. Antimicrob Agents Chemother 63: e00910-00919. https://doi.org/10.1128/aac.00910-19
    [30] Cong Y, Dyall J, Hart BJ, et al. (2016) Evaluation of the activity of lamivudine and zidovudine against Ebola virus. PLoS One 11: e0166318. https://doi.org/10.1371/journal.pone.0166318
    [31] Zang R, Case JB, Yutuc E, et al. (2020) Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc Natl Acad Sci U S A 117: 32105-32113. https://doi.org/10.1073/pnas.2012197117
    [32] Diaz FJ, Aguilar-Jimenez W, Florez-Alvarez L, et al. (2020) Isolation and characterization of an early SARS-CoV-2 isolate from the 2020 epidemic in Medellin, Colombia. Biomedica 40: 148-158. https://doi.org/10.7705/biomedica.5834
    [33] Chosewood L, Wilson D (2009) Biosafety in Microbiological and Biomedical Laboratories.US Department of Health and Human Services 415.
    [34] Zapata-Cardona MI, Florez-Alvarez L, Zapata-Builes W, et al. (2022) Atorvastatin effectively inhibits ancestral and two emerging variants of SARS-CoV-2 in vitro. Front Microbiol 13: 721103. https://doi.org/10.3389/fmicb.2022.721103
    [35] Marin-Palma D, Tabares-Guevara JH, Zapata-Cardona MI, et al. (2021) Curcumin inhibits in vitro SARS-CoV-2 infection in vero E6 cells through multiple antiviral mechanisms. Molecules 26: 6900. https://doi.org/10.3390/molecules26226900
    [36] Zapata Cardona M, Florez-Alvarez L, Gomez-Gallego D, et al. (2022) Comparison among plaque assay, tissue culture infectious dose (TCID50) and real-time RT-PCR for SARS-CoV-2 variants quantification. Iran J Microbiol 14: 291-299. https://doi.org/10.18502/ijm.v14i3.9758
    [37] Moeller NH, Shi K, Demir O, et al. (2021) Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. bioRxiv . https://doi.org/10.1101/2021.04.02.438274
    [38] Su HX, Yao S, Zhao WF, et al. (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 41: 1167-1177. https://doi.org/10.1038/s41401-020-0483-6
    [39] Berman HM, Westbrook J, Feng Z, et al. (2020) The protein data bank. Nucleic Acids Res 28: 235-242. https://doi.org/10.1093/nar/28.1.235
    [40] Curry S (2015) Structural biology: a century-long journey into an unseen world. Interdiscip Sci Rev 40: 308-328. https://doi.org/10.1179/0308018815Z.000000000120
    [41] BIOVIA DSDiscovery studio visualizer software, version 16.1 2017. Available from: https://discover.3ds.com/discovery-studio-visualizer-download.
    [42] Chu CK, Gadthula S, Chen X, et al. (2006) Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-CoV). Antivir Chem Chemother 17: 285-289. https://doi.org/10.1177/095632020601700506
    [43] Hanwell MD, Curtis DE, Lonie DC, et al. (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminformatics 4: 17. https://doi.org/10.1186/1758-2946-4-17
    [44] Kokic G, Hillen HS, Tegunov D, et al. (2021) Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun 12: 279. https://doi.org/10.1038/s41467-020-20542-0
    [45] Koulgi S, Jani V, Uppuladinne M, et al. (2020) Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2. RSC Advances 10: 26792-26803. https://doi.org/10.1039/D0RA04743K
    [46] Wang X, Sacramento CQ, Jockusch S, et al. (2022) Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun Biol 5: 154. https://doi.org/10.1038/s42003-022-03101-9
    [47] Nimgampalle M, Devanathan V, Saxena A (2020) Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. J Biomol Struct Dyn : 1-13. https://doi.org/10.1080/07391102.2020.1782265
    [48] Li Z, Li X, Huang YY, et al. (2020) Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc Natl Acad Sci USA 117: 27381. https://doi.org/10.1073/pnas.2010470117
    [49] Jendele L, Krivak R, Skoda P, et al. (2019) PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Res 47: W345-W349. https://doi.org/10.1093/nar/gkz424
    [50] Schoning-Stierand K, Diedrich K, Fahrrolfes R, et al. (2020) ProteinsPlus: interactive analysis of protein–ligand binding interfaces. Nucleic Acids Res 48: W48-W53. https://doi.org/10.1093/nar/gkaa235
    [51] Elfiky AA (2020) Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 253: 117592. https://doi.org/10.1016/j.lfs.2020.117592
    [52] Narayanan N, Nair DT (2021) Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. Int J Biol Macromol 168: 272-278. https://doi.org/10.1016/j.ijbiomac.2020.12.038
    [53] Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461. https://doi.org/10.1002/jcc.21334
    [54] Ma Y, Wu L, Shaw N, et al. (2015) Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci USA 112: 9436-9441. https://doi.org/10.1073/pnas.1508686112
    [55] Frediansyah A, Tiwari R, Sharun K, et al. (2021) Antivirals for COVID-19: a critical review. Clin Epidemiol Glob Health 9: 90-98. https://doi.org/10.1016/j.cegh.2020.07.006
    [56] Iacob S, Iacob DG (2020) SARS-CoV-2 Treatment approaches: numerous ptions, no certainty for a versatile virus. Front Pharmacol 11. https://doi.org/10.3389/fphar.2020.01224
    [57] Papatheodoridis GV, Dimou E, Papadimitropoulos V (2002) Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 97: 1618-1628. https://doi.org/10.1111/j.1572-0241.2002.05819.x
    [58] Joly V, Yeni P (1995) Treatment of HIV infection with nucleoside analogs: present status. Presse Med 24: 103-110.
    [59] Furman PA, Lam AM, Murakami E (2009) Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends. Future Med Chem 1: 1429-1452. https://doi.org/10.4155/fmc.09.88
    [60] Fiala M, Chow AW, Miyasaki K, et al. (1974) Susceptibility of herpesviruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect at acid pH. J Infect Dis 129: 82-85. https://doi.org/10.1093/infdis/129.1.82
    [61] Lisi L, Lacal PM, Barbaccia ML, et al. (2020) Approaching coronavirus disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochem Pharmacol 180: 11416. https://doi.org/10.1016/j.bcp.2020.114169
    [62] Smith EC, Blanc H, Surdel MC, et al. (2013) Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS pathogens 9: e100356. https://doi.org/10.1371/journal.ppat.1003565
    [63] Agostini ML, Andres EL, Sims AC, et al. (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9: e00221-00218. https://doi.org/10.1128/mBio.00221-18
    [64] Tran L, Tam DNH, Elhadad H, et al. (2022) Evaluation of COVID-19 protease and HIV inhibitors interactions. Acta Pharm 72: 1-8. https://doi.org/10.2478/acph-2022-0010
    [65] Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorganic Med Chem Lett 30: 127377. https://doi.org/10.1016/j.bmcl.2020.127377
    [66] Pinzi L, Rastelli G (2019) Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci 20: 4331. https://doi.org/10.3390/ijms20184331
    [67] Coupez B, Lewis RA (2006) Docking and scoring--theoretically easy, practically impossible?. Curr Med Chem 13: 2995-3003. https://doi.org/10.2174/092986706778521797
    [68] Guedes IA, Pereira FSS, Dardenne LE (2018) Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges. Front Pharmacol 9: 1089. https://doi.org/10.3389/fphar.2018.01089
    [69] Pruijssers AJ, George AS, Schafer A, et al. (2020) Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 32: 107940. https://doi.org/10.1016/j.celrep.2020.107940
    [70] Pruijssers AJ, Denison MR (2019) Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol 35: 57-62. https://doi.org/10.1016/j.coviro.2019.04.002
    [71] Koczor CA, Torres RA, Lewis W (2012) The role of transporters in the toxicity of nucleoside and nucleotide analogs. Expert Opin Drug Metab Toxicol 8: 665-676. https://doi.org/10.1517/17425255.2012.680885
    [72] Eyer L, Nencka R, de Clercq E, et al. (2018) Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antivir Chem Chemother 26: 2040206618761299. https://doi.org/10.1177/2040206618761299
    [73] He X, Quan S, Xu M, et al. (2021) Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. Proc Natl Acad Sci USA 118: e2025866118. https://doi.org/10.1073/pnas.2025866118
    [74] Sankatsing SU, Beijnen JH, Schinkel AH, et al. (2004) P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48: 1073-1081. https://doi.org/10.1128/aac.48.4.1073-1081.2004
    [75] ClinicalTrials.govClinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 (ARTAN-C19) (2021). Available from: https://clinicaltrials.gov/ct2/show/NCT04712357?term=emtricitabine&cond=covid 19&draw=2&rank=1.
    [76] ClinicalTrials.govClinical trial to evaluate the efficacy of different treatments in patients with COVID-19 (2021). Available from: https://clinicaltrials.gov/ct2/show/NCT04890626?term=emtricitabine&cond=covid-19&draw=2.
    [77] ClinicalTrials.govDaily regimen of tenofovir/emtricitabine as prevention for COVID-19 in health care personnel in Colombia (2020). Available from: https://clinicaltrials.gov/ct2/show/NCT04519125?term=emtricitabine&cond=covid-19&draw=2&rank=3.
    [78] Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. (2021) Effect of tenofovir disoproxil fumarate and emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine 38: 100993. https://doi.org/10.1016/j.eclinm.2021.100993
    [79] Gaitan-Duarte HG, Alvarez-Moreno C, Rincon-Rodriguez CJ, et al. (2022) Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine 43: 101242. https://doi.org/10.1016/j.eclinm.2021.101242
    [80] Del Amo J, Polo R, Moreno S, et al. (2020) Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med 173: 536-541. https://doi.org/10.7326/M20-3689
    [81] Moss DM, Kwan WS, Liptrott NJ, et al. (2011) Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 55: 879-887. https://doi.org/10.1128/AAC.00623-10
    [82] Khan RJ, Jha RK, Amera GM, et al. (2021) Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase. J Biomol Struct Dyn 39: 2679-2692. https://doi.org/10.1080/07391102.2020.1753577
    [83] Molavi Z, Razi S, Mirmotalebisohi SA, et al. (2021) Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomed Pharmacother 138: 111544. https://doi.org/10.1016/j.biopha.2021.111544
    [84] Tazikeh-Lemeski E, Moradi S, Raoufi R, et al. (2021) Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study. J Biomol Struct Dyn 39: 4633-4646. https://doi.org/10.1080/07391102.2020.1779133
  • microbiol-09-01-002-s001.pdf
  • This article has been cited by:

    1. Yuan Tian, Hua Guo, Wenyu Shen, Xinrui Yan, Jie Zheng, Kaibiao Sun, Dynamic analysis and validation of a prey-predator model based on fish harvesting and discontinuous prey refuge effect in uncertain environments, 2025, 33, 2688-1594, 973, 10.3934/era.2025044
  • Reader Comments
  • © 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(13232) PDF downloads(192) Cited by(10)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog